SCHEMBL10189774

SCHEMBL10189774

COc1ccc(-c2[nH]nnc2-c2cc(C)c3c(c2)OCO3)c(O[PH](=O)O)c1

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 6/20 0.36
MEN1 O00255 5/20 0.36
KMT2A Q03164 5/20 0.36
HPGD P15428 4/20 0.36
LMNA P02545 4/20 0.36
KDM4E B2RXH2 4/20 0.36
MAPT P10636 4/20 0.36
HTT P42858 3/20 0.36
TDP1 Q9NUW8 3/20 0.36
APP P05067 1/20 0.35
ACHE P22303 1/20 0.35
NPSR1 Q6W5P4 3/20 0.33
SMN1; SMN2 Q16637 2/20 0.33
ALOX15 P16050 1/20 0.33
ALOX12 P18054 1/20 0.33
CLK1 P49759 1/20 0.33
L3MBTL1 Q9Y468 1/20 0.33
CYP1A2 P05177 1/20 0.32
CYP3A4 P08684 1/20 0.32
CYP2D6 P10635 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10189765 0.85 ALOX12 (0.45) ALDH1A1MEN1KMT2AHPGDLMNA
SCHEMBL10189747 0.85 ALPL (0.36) ALDH1A1MEN1KMT2AHPGDLMNA
SCHEMBL10189780 0.84 MEN1 (0.36) ALDH1A1MEN1KMT2AHPGDLMNA
SCHEMBL10189772 0.82 KDM4E (0.38) ALDH1A1MEN1KMT2AHPGDLMNA
SCHEMBL10189773 0.82 EDNRB (0.37) ALDH1A1MEN1KMT2AHPGDLMNA
SCHEMBL10189776 0.79 KDM4E (0.31) ALDH1A1MEN1KMT2AHPGDLMNA
SCHEMBL13077999 0.78 ALDH1A1 (0.44) ALDH1A1MEN1KMT2AHPGDLMNA
SCHEMBL411535 0.78 MEN1 (0.48) ALDH1A1MEN1KMT2AHPGDLMNA
SCHEMBL14847359 0.77 LMNA (0.47) ALDH1A1MEN1KMT2AHPGDLMNA
SCHEMBL13041141 0.77 ALDH1A1 (0.43) ALDH1A1MEN1KMT2AHPGDLMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9175022-B2 Compounds for the treatment of proliferative disorders SYNTA PHARMACEUTICALS CORP. (US) 2015-11-03 US disclosed
US-8501790-B2 Compounds for the treatment of proliferative disorders SYNTA PHARMACEUTICALS CORP. (US) 2013-08-06 US disclosed
US-20120022118-A1 COMPOUNDS FOR THE TREATMENT OF PROLIFERATIVE DISORDERS SYNTA PHARMACEUTICALS CORP. 2012-01-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120022118-A1 COMPOUNDS FOR THE TREATMENT OF PROLIFERATIVE DISORDERS RB1, MKI67, MAPRE1 ALDH1A1 1872/4885MEN1 1571/4885KMT2A 2808/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.